Immunotherapy Advances in Urothelial Carcinoma

Rohit K. Jain, Travis Snyders, Lakshminarayanan Nandgoapal, Rohan Garje, Yousef Zakharia, Shilpa Gupta

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Several immunotherapy trials are ongoing in non-metastatic setting to maximize responses upfront. Despite the promising responses with immunotherapy, majority of patients do not respond to monotherapy and combination approaches would be the path moving forward to maximize responses. In addition, novel therapies are needed for patients who progress on checkpoint inhibitors. There is still a lot to be done to better understand predictive biomarkers, optimal combination, and sequences to improve clinical outcomes in urothelial carcinoma.

Original languageEnglish (US)
Article number79
JournalCurrent treatment options in oncology
Volume19
Issue number12
DOIs
StatePublished - Dec 1 2018

Fingerprint

Immunotherapy
Carcinoma
Platinum
Cisplatin
Therapeutics
Biomarkers
Safety
Drug Therapy
pembrolizumab

Keywords

  • Biomarkers
  • Checkpoint inhibitors
  • Immunotherapy
  • Urothelial carcinoma

PubMed: MeSH publication types

  • Journal Article
  • Review

Cite this

Jain, R. K., Snyders, T., Nandgoapal, L., Garje, R., Zakharia, Y., & Gupta, S. (2018). Immunotherapy Advances in Urothelial Carcinoma. Current treatment options in oncology, 19(12), [79]. https://doi.org/10.1007/s11864-018-0598-x

Immunotherapy Advances in Urothelial Carcinoma. / Jain, Rohit K.; Snyders, Travis; Nandgoapal, Lakshminarayanan; Garje, Rohan; Zakharia, Yousef; Gupta, Shilpa.

In: Current treatment options in oncology, Vol. 19, No. 12, 79, 01.12.2018.

Research output: Contribution to journalReview article

Jain, RK, Snyders, T, Nandgoapal, L, Garje, R, Zakharia, Y & Gupta, S 2018, 'Immunotherapy Advances in Urothelial Carcinoma', Current treatment options in oncology, vol. 19, no. 12, 79. https://doi.org/10.1007/s11864-018-0598-x
Jain RK, Snyders T, Nandgoapal L, Garje R, Zakharia Y, Gupta S. Immunotherapy Advances in Urothelial Carcinoma. Current treatment options in oncology. 2018 Dec 1;19(12). 79. https://doi.org/10.1007/s11864-018-0598-x
Jain, Rohit K. ; Snyders, Travis ; Nandgoapal, Lakshminarayanan ; Garje, Rohan ; Zakharia, Yousef ; Gupta, Shilpa. / Immunotherapy Advances in Urothelial Carcinoma. In: Current treatment options in oncology. 2018 ; Vol. 19, No. 12.
@article{648daa6805ca4578824f65870ed46733,
title = "Immunotherapy Advances in Urothelial Carcinoma",
abstract = "Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Several immunotherapy trials are ongoing in non-metastatic setting to maximize responses upfront. Despite the promising responses with immunotherapy, majority of patients do not respond to monotherapy and combination approaches would be the path moving forward to maximize responses. In addition, novel therapies are needed for patients who progress on checkpoint inhibitors. There is still a lot to be done to better understand predictive biomarkers, optimal combination, and sequences to improve clinical outcomes in urothelial carcinoma.",
keywords = "Biomarkers, Checkpoint inhibitors, Immunotherapy, Urothelial carcinoma",
author = "Jain, {Rohit K.} and Travis Snyders and Lakshminarayanan Nandgoapal and Rohan Garje and Yousef Zakharia and Shilpa Gupta",
year = "2018",
month = "12",
day = "1",
doi = "10.1007/s11864-018-0598-x",
language = "English (US)",
volume = "19",
journal = "Current Treatment Options in Oncology",
issn = "1527-2729",
publisher = "Springer New York",
number = "12",

}

TY - JOUR

T1 - Immunotherapy Advances in Urothelial Carcinoma

AU - Jain, Rohit K.

AU - Snyders, Travis

AU - Nandgoapal, Lakshminarayanan

AU - Garje, Rohan

AU - Zakharia, Yousef

AU - Gupta, Shilpa

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Several immunotherapy trials are ongoing in non-metastatic setting to maximize responses upfront. Despite the promising responses with immunotherapy, majority of patients do not respond to monotherapy and combination approaches would be the path moving forward to maximize responses. In addition, novel therapies are needed for patients who progress on checkpoint inhibitors. There is still a lot to be done to better understand predictive biomarkers, optimal combination, and sequences to improve clinical outcomes in urothelial carcinoma.

AB - Checkpoint inhibitors have monumentally transformed the treatment of metastatic urothelial carcinoma. While the efficacy and safety of the different agents are similar in platinum-refractory metastatic urothelial carcinoma, pembrolizumab is the only agent that was superior to chemotherapy in a randomized phase III trial. Pembrolizumab and atezolizumab are also approved as first-line therapies in cisplatin-ineligible metastatic urothelial carcinoma. Several immunotherapy trials are ongoing in non-metastatic setting to maximize responses upfront. Despite the promising responses with immunotherapy, majority of patients do not respond to monotherapy and combination approaches would be the path moving forward to maximize responses. In addition, novel therapies are needed for patients who progress on checkpoint inhibitors. There is still a lot to be done to better understand predictive biomarkers, optimal combination, and sequences to improve clinical outcomes in urothelial carcinoma.

KW - Biomarkers

KW - Checkpoint inhibitors

KW - Immunotherapy

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85058544202&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058544202&partnerID=8YFLogxK

U2 - 10.1007/s11864-018-0598-x

DO - 10.1007/s11864-018-0598-x

M3 - Review article

C2 - 30554335

AN - SCOPUS:85058544202

VL - 19

JO - Current Treatment Options in Oncology

JF - Current Treatment Options in Oncology

SN - 1527-2729

IS - 12

M1 - 79

ER -